Archive · 22 Dec 2025
PlasmaGen Biosciences Raises ₹150 Crore for Global Expansion
PlasmaGen Biosciences, a company that makes medicines from plasma, just got ₹150 crore from investors.
This money will help them sell their products in other countries and grow in India.
They make important medicines like albumin and immunoglobulins that help people with different health problems.
Big investors like ViNS Bioproducts and others believe in their work.
This is not their first time getting money from investors; they have raised a total of ₹600 crore since they started in 2010.
Now, they want to use this new money to become even bigger and help more people around the world.
PlasmaGen Biosciences raised ₹150 crore in a new equity financing round, valuing the company at over ₹1,500 crore.
ViNS Bioproducts led the investment round with participation from existing investors and other pharma companies.
The funds will be used for international expansion and strengthening the company's presence in India.
PlasmaGen's key products include albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin, and RhD immunoglobulin (anti-D).
The company has raised a total of ₹600 crore in funding since its inception in 2010.
- Who
- PlasmaGen Biosciences, a biopharmaceutical company
- What
- Raised ₹150 crore in equity financing for global expansion
- When
- Recent funding round, previous rounds in 2023 and 2017
- Where
- India, with plans to expand internationally
- Why
- To expand into global markets and strengthen presence in India
- Funding Amount
- ₹150 crore
- Company Valuation
- Over ₹1,500 crore
- Lead Investor
- ViNS Bioproducts
- Key Products
- Albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin, RhD immunoglobulin (anti-D)
- Total Funding
- ₹600 crore since inception in 2010
- Manufacturing Facility
- Started commercial operations last year
- Target Markets
- Key export markets identified for international expansion